Hasbro Introduces Ms. Monopoly – First Game in the Franchise that Celebrates Women Trailblazers
10.9.2019 16:00:00 EEST | Business Wire | Press release
Today, Hasbro, Inc. is introducing the first-ever game in the Monopoly franchise that celebrates women trailblazers with Ms. Monopoly. The Ms. Monopoly game marks the first time in the franchise’s history where a new character will grace the cover – and while Mr. Monopoly is a real-estate mogul, Ms. Monopoly is an advocate whose mission is to invest in female entrepreneurs.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190910005160/en/
Ms. Monopoly was created to inspire everyone, young and old as it spotlights women who have challenged the status quo. To celebrate, in lieu of Monopoly winnings, Hasbro surprised young female inventors and entrepreneurs with the recognition they deserve –approximately $20,580 in REAL money to fuel their inventive spirit and further their projects – which just so happens to be the same amount of Monopoly money featured in the game. You can see all of their reactions to the surprise here. All of the young inventors come from very different backgrounds, but with a common goal to help others using their inventions:
- Sophia Wang, a 16-year-old from Connecticut invented a device that can detect sinkholes before they occur, and after two years of work, her prototype is now 93% accurate. She is hoping to get it patented and in the hands of communities in Florida that are vulnerable to sinkholes.
- Gitanjali Rao, a 13-year-old from Denver came up with an invention that helps detect lead in drinking water so that individuals can do the test themselves and get results sooner. Her goal is to create an inexpensive, easy to use, portable device so that people all around the world can use it.
- Ava Canney, a 16-year-old from Ireland, invented a spectrometer that measures the amount of dye in candy and soda. After studying the harmful effects of additives in our food, Ava set out to help people make educated decisions about the toxins they put into their bodies.
“Through the introduction of Ms. Monopoly and the money these young women have received to invest in their future projects, we want to recognize and celebrate the many contributions women have made to our society and continue to make on a daily basis,” said Jen Boswinkel, Senior Director, Global Brand Strategy and Marketing, Hasbro.
Hitting shelves in mid-September, Ms. Monopoly gives new meaning to the franchise, as properties are replaced by groundbreaking inventions and innovations made possible by women throughout history and instead of building houses, you build business headquarters. From inventions like WiFi to chocolate chip cookies, solar heating and modern shapewear, Ms. Monopoly celebrates everything from scientific advancements to everyday accessories – all created by women.
Ms. Monopoly is also the first-ever game where women make more than men – a fun spin in the game that creates a world where women have an advantage often enjoyed by men. However, if men play their cards right, they can make more money too.
Ms. Monopoly is available for pre-order now at Walmart and will be available at most major retailers nationwide and in select countries globally starting September 2019 for a suggested retail price of $19.99.
About Hasbro
Hasbro (NASDAQ: HAS) is a global play and entertainment company committed to Creating the World's Best Play Experiences. From toys and games to television, movies, digital gaming and consumer products, Hasbro offers a variety of ways for audiences to experience its iconic brands, including NERF, MY LITTLE PONY, TRANSFORMERS, PLAY-DOH, MONOPOLY, BABY ALIVE, MAGIC: THE GATHERING and POWER RANGERS, as well as premier partner brands. Through its entertainment labels, Allspark Pictures and Allspark Animation, the Company is building its brands globally through great storytelling and content on all screens. Hasbro is committed to making the world a better place for children and their families through corporate social responsibility and philanthropy. Hasbro ranked No. 13 on the 2019 100 Best Corporate Citizens list by CR Magazine, and has been named one of the World’s Most Ethical Companies® by Ethisphere Institute for the past eight years. Learn more at www.hasbro.com, and follow us on Twitter (@Hasbro) and Instagram (@Hasbro).
HAS-B
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190910005160/en/
Contact information
Kristina Timmins
Hasbro, Inc.
Tel: 401-727-5973
Kristina.Timmins@hasbro.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
